Challenges with overall survival as an endpoint for efficacy assessment in first line metastatic breast cancer randomized controlled clinical trials and the investigation of truncated overall survival as an alternative endpoint
Crossref DOI link: https://doi.org/10.1007/s12254-014-0164-6
Published Online: 2014-08-20
Published Print: 2014-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Neate, Colin
Strasak, Alexander
Burger, Hans Ulrich
Tong, Barbara
Kaiser, Lee
Text and Data Mining valid from 2014-08-20